Avid Logo June 2022.jpg
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
06 mars 2024 23h58 HE | Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Antion Logo - RGB - Web version-01.png
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
06 mars 2024 06h55 HE | ANTION BIOSCIENCES SA
Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics
22157.jpg
Asia-Pacific Gene Editing Technology Research Report 2024
29 févr. 2024 10h03 HE | Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Gene Editing Technologies Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.The...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
28 févr. 2024 16h05 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly...
22157.jpg
Europe Cell and Gene Therapy Manufacturing QC Market Research Report 2024
28 févr. 2024 09h29 HE | Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
28 févr. 2024 07h05 HE | uniQure Inc.
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
27 févr. 2024 16h30 HE | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2023-2033: Rising Number of Approved Therapies and Increasing Need for Expanded Infrastructure
27 févr. 2024 06h46 HE | Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...
ocugen_4C_LOGO (002).png
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
26 févr. 2024 08h30 HE | Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
22 févr. 2024 16h05 HE | Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...